IGMS

IGMS

USD

IGM Biosciences Inc. Common Stock

$1.218-0.032 (-2.544%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$1.250

高値

$1.270

安値

$1.215

出来高

0.11M

企業ファンダメンタルズ

時価総額

73.2M

業種

バイオテクノロジー

United States

取引統計

平均出来高

0.18M

取引所

NMS

通貨

USD

52週レンジ

安値 $0.92現在値 $1.218高値 $22.5

AI分析レポート

最終更新: 2025年5月23日
AIによる生成データソース: Yahoo Finance, Bloomberg, SEC

IGMS: IGM Biosciences Inc. Common Stock – A Look at Recent Trends and What's Next

Stock Symbol: IGMS Generate Date: 2025-05-23 15:19:05

Let's break down what's been happening with IGM Biosciences and what the numbers might be telling us.

The Latest Buzz (News Sentiment)

Right now, we don't have specific news headlines to go on, so the sentiment from recent news is a bit of a blank slate. This means we're relying heavily on the price action and technical indicators to get a feel for what's driving the stock. Sometimes, no news is... well, just no news, and other factors take the wheel.

What the Stock Price Has Been Doing (Price Action)

Looking at the past few months, IGMS has seen its share of ups and downs. Back in late February, it was hovering around $1.30-$1.40. Then, through March, we saw a gradual drift lower, dipping below $1.20 by late March and early April. It even touched a 52-week low of $0.92 in early April.

However, things picked up mid-April, with the stock climbing back towards the $1.30-$1.40 range. More recently, from early May, there's been another slight pullback, settling around the $1.15-$1.25 mark. Today, May 23rd, the stock is trading around $1.22. The trading volume today, at 33,439 shares, is quite a bit lower than its average, which sits around 173,942. This lower volume on the current day's price action might suggest less conviction behind the move.

The AI's analysis points to the current price being very close to a support level at $1.19. This is an interesting point to note.

Putting It All Together: Outlook & Strategy Ideas

Given the lack of specific news, we're leaning on the technical signals and the AI's insights. The overall picture here suggests a potential buying opportunity for those looking at a short-term trade.

Why does it look that way?

  • Technical Strength: The AI highlights several bullish technical indicators. The DMI (Directional Movement Index) shows a positive trend, and the MACD (Moving Average Convergence Divergence) has a "golden cross," which is often seen as a bullish signal.
  • Volume Spike (Earlier): While today's volume is low, the AI notes a recent surge in trading volume (8.3x average) indicating strong buying pressure. This suggests some significant interest has recently entered the stock.
  • Support Level: The current price being near the $1.19 support level is key. This could act as a floor, making it a potentially attractive entry point.
  • Value Potential: The P/E ratio, while negative, is better than the industry average, which the AI flags as a sign of value.

On the flip side, there are some things to be aware of:

  • Fundamental Weaknesses: The company's revenue growth is low, and its Return on Equity (ROE) is quite poor. Also, the debt-to-equity ratio is very high, which is a significant concern. These fundamental issues mean this isn't a long-term "buy and hold" candidate based on these metrics.
  • Risk Factors: The AI points out high industry-relative debt, small market capitalization, and low trading volume as risk factors. These are important to keep in mind.

So, what's the apparent near-term leaning? It seems to favor potential buyers, especially for those interested in short-term trading.

  • Potential Entry Consideration: If you're considering a move, the area around $1.19 to $1.20 looks like a potential entry point. This aligns with the identified support level and the AI's suggested entry range.
  • Potential Exit/Stop-Loss Consideration: To manage risk, a stop-loss around $1.08 would make sense. This is below recent lows and provides a clear point to exit if the stock moves against expectations. For taking profits, the AI suggests a take-profit level of $1.23. This is a short-term target, reflecting the "short-term trading" investment horizon.

Company Context

IGM Biosciences is a biotechnology company focused on developing antibodies for cancer and autoimmune diseases. It's a relatively small company with 54 employees and a market cap of about $73 million. In the biotech world, news about clinical trials, drug approvals, or research breakthroughs can cause huge swings. Without specific news, we're left to interpret the price action and technicals, but always remember that biotech stocks can be quite volatile. The 52-week high of $22.5 compared to the current price shows just how much this stock can move.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in stocks carries inherent risks, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial professional before making any investment decisions.

関連ニュース

Analyst Upgrades

Truist Securities Maintains Hold on IGM Biosciences, Lowers Price Target to $1

Truist Securities analyst Asthika Goonewardene maintains IGM Biosciences with a Hold and lowers the price target from $2 to $1.

もっと見る
Truist Securities Maintains Hold on IGM Biosciences, Lowers Price Target to $1

AI予測Beta

AI推奨

弱気

更新日時: 2025年6月12日 15:57

弱気中立強気

57.8% 信頼度

リスクと取引

リスクレベル4/5
高リスク
適しているのは
バリュー
取引ガイド

エントリーポイント

$1.36

利確

$1.39

損切り

$1.23

主要因子

DMIは弱気トレンドを示しており (ADX:17.3、+DI:8.4、-DI:13.2)、注意が必要です
現在の価格はサポートレベル(1.37ドル)に非常に接近しており、強力な買い機会を示唆しています
出来高は平均(3,412)の8.1倍で、極めて強い買い圧力を示しています
MACD -0.0029はシグナルライン-0.0008の下にあり、弱気クロスオーバーを示しています

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。